Evolving paradigms in locally advanced rectal cancer: the means justify the ends

J Natl Cancer Inst. 2023 Dec 6;115(12):1439-1441. doi: 10.1093/jnci/djad196.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Humans
  • Neoadjuvant Therapy*
  • Receptors, Vascular Endothelial Growth Factor
  • Recombinant Fusion Proteins
  • Rectal Neoplasms* / therapy

Substances

  • aflibercept
  • Receptors, Vascular Endothelial Growth Factor
  • Recombinant Fusion Proteins